Inventor · disambiguated record
Geoffrey Parsons
Also filed as: PARSONS GEOFFREY · PARSONS GEOFFREY B · PARSONS GEOFFREY BLACKBURN
1 granted patent·10 pending applications·1 citations·filing 2002–2025
17Inventor score
Files withBLUEBIRD BIO INC4MEDIGENE IMMUNOTHERAPIES GMBH2FLAGSHIP PIONEERING INNOVATIONS V INC1GENZYME CORP1REGENERON PHARMA1
Top patents by PatentIndex Score
11 records- 0174US12344654B2Mage A4 T cell receptorsMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2020·Granted Jul 1, 2025·1 cites·26 claims
- 0262US2025346648A1Mage a4 t cell receptorsMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2025·Application pending·0 cites
- 0361US2024327867A1Anellovirus constructs comprising recombination sites and cross-packaging of anellovector particles and genetic elementsFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2024·Application pending·0 cites
- 0452US2025082756A1Muc16 chimeric antigen receptorsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0547US2004143104A1Methods of treating diabetes and other blood sugar disordersFiled 2003·Application pending·0 cites
- 0645US2005107318A1Methods of treating diabetes and other blood sugar disordersFiled 2003·Application pending·0 cites
- 0738US2004002468A1Methods of treating diabetes and other blood sugar disordersGENZYME CORP·Filed 2002·Application pending·0 cites
- 0830US2019365814A1Vcn enhancer compositions and methods of using the sameBLUEBIRD BIO INC·Filed 2018·Application pending·0 cites
- 0927US2022323612A1Gene therapy of neuronal ceroid lipofuscinosesBLUEBIRD BIO INC·Filed 2017·Application pending·0 cites
- 1025US2020071721A1Gene therapy for mucopolysaccharidosis, type iiBLUEBIRD BIO INC·Filed 2017·Application pending·0 cites
- 1125US2022339296A1Gene therapy for mucopolysaccharidosis, type iBLUEBIRD BIO INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Geoffrey Parsons files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →